Nektar Therapeutics (NKTR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 21.90 is considered Undervalued compared with the five-year average of -2.74. The fair price of Nektar Therapeutics (NKTR) is between 160.31 to 214.90 according to relative valuation method. Compared to the current price of 68.36 USD , Nektar Therapeutics By Undervalued By 57.36%.

Relative Value

Fair Zone

160.31-214.90

Current Price：68.36

57.36%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Nektar Therapeutics (NKTR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Nektar Therapeutics (NKTR) has a current Price-to-Book (P/B) ratio of 10.03. Compared to its 3-year average P/B ratio of 2.03, the current P/B ratio is approximately 394.83% higher. Relative to its 5-year average P/B ratio of 2.18, the current P/B ratio is about 359.85% higher. Nektar Therapeutics (NKTR) has a Forward Free Cash Flow (FCF) yield of approximately -21.55%. Compared to its 3-year average FCF yield of -119.98%, the current FCF yield is approximately -82.04% lower. Relative to its 5-year average FCF yield of -85.33%, the current FCF yield is about -74.74% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NKTR competitors is 211.43, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR.O) exhibits a P/S ratio of 21.90, which is -89.64% above the industry average. Given its robust revenue growth of -51.13%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NKTR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NKTR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NKTR currently overvalued or undervalued?

What is Nektar Therapeutics (NKTR) fair value?

NKTR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Nektar Therapeutics (NKTR) is between 160.31 to 214.90 according to relative valuation method.

How does NKTR's valuation metrics compare to the industry average?

The average P/S ratio for NKTR's competitors is 211.43, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR) exhibits a P/S ratio of 21.90, which is -89.64% above the industry average. Given its robust revenue growth of -51.13%, this premium appears unsustainable.

What is the current P/B ratio for Nektar Therapeutics (NKTR) as of Mar 03 2026?

As of Mar 03 2026, Nektar Therapeutics (NKTR) has a P/B ratio of 10.03. This indicates that the market values NKTR at 10.03 times its book value.

What is the current FCF Yield for Nektar Therapeutics (NKTR) as of Mar 03 2026?

As of Mar 03 2026, Nektar Therapeutics (NKTR) has a FCF Yield of -21.55%. This means that for every dollar of Nektar Therapeutics's market capitalization, the company generates -21.55 cents in free cash flow.

What is the current Forward P/E ratio for Nektar Therapeutics (NKTR) as of Mar 03 2026?

As of Mar 03 2026, Nektar Therapeutics (NKTR) has a Forward P/E ratio of -4.58. This means the market is willing to pay $-4.58 for every dollar of Nektar Therapeutics's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Nektar Therapeutics (NKTR) as of Mar 03 2026?

As of Mar 03 2026, Nektar Therapeutics (NKTR) has a Forward P/S ratio of 21.90. This means the market is valuing NKTR at $21.90 for every dollar of expected revenue over the next 12 months.

NKTR Valuation